Developer docs
API playgroundTry for free, no card

Search company profiles

MacroGenics

Full company profile

uuid0003eae

Namestring
MacroGenics
Legal namestring
MacroGenics, Inc.
Websiteurl
macrogenics.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

MacroGenics is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Rockville, Maryland, that develops antibody-based therapeutics for cancer, autoimmune disease, and infectious disease. Its pipeline is built on four proprietary protein-engineering platforms: DART® (bispecific antibodies), TRIDENT® (trivalent bispecifics with CD137 costimulation), an antibody-drug conjugate (ADC) platform, and an Fc optimization platform. Lead wholly-owned clinical assets include lorigerlimab (PD-1 × CTLA-4 bispecific, Phase 2 LINNET), MGC026 (B7-H3 ADC, Phase 1), MGC028 (ADAM9 ADC, Phase 1), MGD024 (CD123 × CD3, Phase 1), and MGC030 (IND-enabling, Q3 2026 submission planned).

The company generates revenue primarily through licensing and milestone payments on partnered assets rather than direct product sales. Three FDA-approved products have originated from its pipeline: TZIELD (teplizumab, licensed to Sanofi for type 1 diabetes), ZYNYZ (retifanlimab, licensed to Incyte for PD-1 inhibitor indications), and margetuximab (anti-HER2). MacroGenics retains development control and earns milestones, royalties, and opt-in fees; it has also monetized royalty streams via a $60M capped royalty purchase with Sagard Healthcare Partners on ZYNYZ. In May 2026 MacroGenics agreed to sell its in-house GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5M upfront, transferring approximately 140 employees and pivoting to a pipeline-focused model with contract-manufacturing supply. Customers are global pharmaceutical partners (Sanofi, Incyte, Gilead), not end patients or providers, and revenue is recognized when milestones or royalties are earned under these collaboration agreements.

Short descriptiontext

MacroGenics is a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics — including bispecific DART molecules, ADCs, and T-cell engagers — for oncology, hematology, and autoimmune diseases, commercializing through licensing partnerships with Sanofi, Incyte, and Gilead.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody therapeutics, bispecific antibodies, antibody-drug conjugates, cancer immunotherapy, biopharmaceutical development
Industry4 codes
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Royalty Revenue
TypeLicensing Royalties
Description

MacroGenics generates revenue through licensing agreements with pharmaceutical partners. The company licenses its developed products to partners like Incyte (ZYNYZ/retifanlimab) and receives milestone payments, royalty payments on net sales, and potential opt-in fees.

globenewswire.com
2Milestone Payments
TypeLicensing Royalties
Description

The company receives regulatory and commercial milestone payments from partners upon achievement of predetermined development and approval milestones. Recent example: $24.5M from Sanofi for TZIELD FDA accelerated approval.

globenewswire.com
3Royalty Monetization
TypeLicensing Royalties
Description

MacroGenics sells capped royalty interests to financial partners (e.g., Sagard Healthcare Partners) for upfront non-dilutive capital. The company received $60M upfront from Sagard for ZYNYZ royalties, with rights reverting after specified return thresholds.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1TZIELD
Description

Disease-modifying therapy for type 1 diabetes (teplizumab-mzwv) - FDA approved for delaying decline in endogenous insulin production in children aged 8-17 with stage 3 type 1 diabetes

macrogenics.com
+1 more record
Core offering1 text field

MacroGenics is a clinical-stage biopharmaceutical company that discovers and develops next-generation antibody-based therapeutics for cancer, hematologic malignancies, and autoimmune diseases. Its pipeline encompasses bispecific checkpoint antibodies, antibody-drug conjugates (ADCs), and T-cell engagers built on proprietary DART®, TRIDENT®, ADC, and Fc Optimization platforms, with three FDA-approved therapies (TZIELD, ZYNYZ, margetuximab) licensed to large pharma partners for global commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • FDA accelerated approval of TZIELD (teplizumab) as first disease-modifying therapy for type 1 diabetes
+2 more records
Product overview1 text field

MacroGenics is a clinical-stage biopharmaceutical company developing next-generation antibody-based therapies for cancer treatment. The company's proprietary technology platforms include DART® (bispecific antibodies), TRIDENT® (trivalent bispecifics), and Fc Optimization. The core pipeline consists of proprietary candidates including Lorigerlimab (PD-1×CTLA-4 bispecific), MGC026 (B7-H3 ADC), MGC028 (ADAM9 ADC), MGD024 (CD123×CD3), and MGC030. MacroGenics also advances partnered programs including TZIELD (Type 1 Diabetes, licensed to Sanofi), ZYNYZ/retifanlimab (PD-1 inhibitor, licensed to Incyte), Flotetuzumab, Tebotelimab, Margetuximab, and IMGC936. The company operates manufacturing capabilities in Maryland and has strategic collaborations with Incyte, Gilead, and Sanofi.

Product and service5 records
1Lorigerlimab (MGD019)
CategoryOncology — Bispecific Checkpoint Inhibitor
Description

Bispecific DART molecule simultaneously targeting PD-1 and CTLA-4 checkpoint receptors to deliver enhanced anti-tumor activity in solid tumors, with the Phase 2 LINNET study evaluating the candidate in gynecologic cancers.

2MGC026 (B7-H3 ADC)
CategoryOncology — Antibody-Drug Conjugate
Description

Glycan-linked, exatecan-based antibody-drug conjugate targeting B7-H3 for the treatment of solid tumors, currently in a Phase 1 clinical study.

3MGC028 (ADAM9 ADC)
CategoryOncology — Antibody-Drug Conjugate
Description

ADAM9-targeted, glycan-linked, exatecan-based antibody-drug conjugate for the treatment of solid tumors, currently in a Phase 1 clinical study.

4MGD024 (CD123 × CD3)
CategoryHematology — Bispecific T-cell Engager
Description

Bispecific DART molecule targeting CD123 and CD3 for treatment of hematological malignancies, particularly acute myeloid leukemia (AML), currently in a Phase 1 clinical trial.

5MGC030
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

MacroGenics partnered with Sanofi for TZIELD (teplizumab), a drug for delaying the decline of endogenous insulin production in children aged 8-17 with stage 3 type 1 diabetes. Sanofi holds commercialization rights while MacroGenics receives milestone payments and royalties. MacroGenics received a $24.5M regulatory milestone following FDA accelerated approval and is eligible for up to $305M in additional milestones plus single-digit royalties on global net sales.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-05-11
Description

Bora Pharmaceuticals acquired MacroGenics' GMP drug substance manufacturing operations including the Rockville, Maryland facility and Frederick warehouse for $122.5M upfront plus up to $5M milestones. Approximately 140 employees transferred to Bora. The transaction shifts MacroGenics to a pipeline-focused model while maintaining access to manufacturing through a long-term supply arrangement. Expected to close Q3 2026.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Global collaboration for ZYNYZ (retifanlimab), a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte. Incyte markets ZYNYZ in the US for Merkel cell carcinoma and anal cancer, with European Commission approval secured for anal cancer. MacroGenics eligible for up to $540M in milestones.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic collaboration for multiple programs with MacroGenics eligible for up to $1.6 billion in potential milestones across all programs.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Genmab is a leading bispecific antibody platform company (Duobody® platform) and developer of approved therapeutics including epcoritamab. Highly comparable to MacroGenics given shared focus on bispecific antibody engineering and oncology/hematology indications.

TypeDirect peer
Description

Zymeworks develops bispecific and multifunctional antibody therapeutics using its Azymetric™ and EFECT™ platforms. Directly comparable as a clinical-stage antibody engineering company pursuing similar oncology targets and partnership-driven commercialization strategies.

TypeDirect peer
Description

Mersana develops antibody-drug conjugates using its Dolasynthen and Immunosynthen platforms, focused on oncology indications. Closely comparable to MacroGenics' ADC franchise (MGC026, MGC028) given shared modality focus and clinical-stage profile.

TypeDirect peer
Description

Harpoon develops T-cell engagers using its TriTAC and ProTriTAC platforms, including HP568 and other clinical-stage oncology assets. Directly comparable to MacroGenics' TRIDENT® T-cell engager platform and bispecific checkpoint approach.

TypeDirect peer
Description

Bolt is a clinical-stage ADC developer using its Boltbody™ ISAC platform combining tumor-targeting antibodies with immune stimulants. Comparable to MacroGenics' ADC pipeline given shared focus on next-generation antibody-drug conjugate modalities in oncology.

TypeEmerging player
Description

CytomX develops probody therapeutics — masked antibodies activated in the tumor microenvironment — with multiple partnered programs. Comparable to MacroGenics given shared focus on engineering antibody-based cancer therapeutics with proprietary platforms and major pharma collaborations.

TypeEmerging player
Description

Compass Therapeutics is a clinical-stage bispecific antibody developer (CTX-009, CTX-112) with platforms in oncology. Comparable as a smaller-scale bispecific antibody developer with similar clinical-stage profile and partnership-oriented business model.

TypeBroad incumbent
Description

Exelixis is a commercial-stage oncology biotech (cabozantinib/CABOMETYX) with a marketed product franchise and pipeline. Comparable to MacroGenics as an oncology-focused biotech, though Exelixis is significantly larger and operates a direct commercial model versus MacroGenics' partner-driven approach.

TypeBroad incumbent
Description

Blueprint Medicines is a commercial-stage precision oncology company (AYVAKIT, GAVRETO). Comparable as a similarly sized clinical/commercial biotech with partnered and proprietary oncology assets, though Blueprint has broader kinase inhibitor focus versus MacroGenics' antibody focus.

TypeBroad incumbent
Description

Iovance is a clinical/commercial-stage cell therapy company (AMTAGVI for melanoma) at a comparable scale to MacroGenics. Comparable as a similarly-sized public biotech with FDA-approved therapy, ongoing clinical pipeline, and capital needs typical of late-stage biotech.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors25 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MacroGenics

Biopharmaceuticalsmacrogenics.com

MacroGenics is a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics — including bispecific DART molecules, ADCs, and T-cell engagers — for oncology, hematology, and autoimmune diseases, commercializing through licensing partnerships with Sanofi, Incyte, and Gilead.

What MacroGenics does

MacroGenics is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Rockville, Maryland, that develops antibody-based therapeutics for cancer, autoimmune disease, and infectious disease. Its pipeline is built on four proprietary protein-engineering platforms: DART® (bispecific antibodies), TRIDENT® (trivalent bispecifics with CD137 costimulation), an antibody-drug conjugate (ADC) platform, and an Fc optimization platform. Lead wholly-owned clinical assets include lorigerlimab (PD-1 × CTLA-4 bispecific, Phase 2 LINNET), MGC026 (B7-H3 ADC, Phase 1), MGC028 (ADAM9 ADC, Phase 1), MGD024 (CD123 × CD3, Phase 1), and MGC030 (IND-enabling, Q3 2026 submission planned).

The company generates revenue primarily through licensing and milestone payments on partnered assets rather than direct product sales. Three FDA-approved products have originated from its pipeline: TZIELD (teplizumab, licensed to Sanofi for type 1 diabetes), ZYNYZ (retifanlimab, licensed to Incyte for PD-1 inhibitor indications), and margetuximab (anti-HER2). MacroGenics retains development control and earns milestones, royalties, and opt-in fees; it has also monetized royalty streams via a $60M capped royalty purchase with Sagard Healthcare Partners on ZYNYZ. In May 2026 MacroGenics agreed to sell its in-house GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5M upfront, transferring approximately 140 employees and pivoting to a pipeline-focused model with contract-manufacturing supply. Customers are global pharmaceutical partners (Sanofi, Incyte, Gilead), not end patients or providers, and revenue is recognized when milestones or royalties are earned under these collaboration agreements.

MacroGenics firmographics

Firmographics
Name
MacroGenics
Legal name
MacroGenics, Inc.
Website
https://macrogenics.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
251–500 employees
Short description
MacroGenics is a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics — including bispecific DART molecules, ADCs, and T-cell engagers — for oncology, hematology, and autoimmune diseases, commercializing through licensing partnerships with Sanofi, Incyte, and Gilead.
Ownership category
akta.pro rank

MacroGenics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Antibody therapeutics
  • Bispecific antibodies
  • Antibody-drug conjugates
  • Cancer immunotherapy
  • Biopharmaceutical development

Where MacroGenics is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

MacroGenics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Royalty Revenue: MacroGenics generates revenue through licensing agreements with pharmaceutical partners. The company licenses its developed products to partners like Incyte (ZYNYZ/retifanlimab) and receives milestone payments, royalty payments on net sales, and potential opt-in fees.
  2. Milestone Payments: The company receives regulatory and commercial milestone payments from partners upon achievement of predetermined development and approval milestones. Recent example: $24.5M from Sanofi for TZIELD FDA accelerated approval.
  3. Royalty Monetization: MacroGenics sells capped royalty interests to financial partners (e.g., Sagard Healthcare Partners) for upfront non-dilutive capital. The company received $60M upfront from Sagard for ZYNYZ royalties, with rights reverting after specified return thresholds.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

MacroGenics product offering

Product offering

Core offering

MacroGenics is a clinical-stage biopharmaceutical company that discovers and develops next-generation antibody-based therapeutics for cancer, hematologic malignancies, and autoimmune diseases. Its pipeline encompasses bispecific checkpoint antibodies, antibody-drug conjugates (ADCs), and T-cell engagers built on proprietary DART®, TRIDENT®, ADC, and Fc Optimization platforms, with three FDA-approved therapies (TZIELD, ZYNYZ, margetuximab) licensed to large pharma partners for global commercialization.

Product overview

MacroGenics is a clinical-stage biopharmaceutical company developing next-generation antibody-based therapies for cancer treatment. The company's proprietary technology platforms include DART® (bispecific antibodies), TRIDENT® (trivalent bispecifics), and Fc Optimization. The core pipeline consists of proprietary candidates including Lorigerlimab (PD-1×CTLA-4 bispecific), MGC026 (B7-H3 ADC), MGC028 (ADAM9 ADC), MGD024 (CD123×CD3), and MGC030. MacroGenics also advances partnered programs including TZIELD (Type 1 Diabetes, licensed to Sanofi), ZYNYZ/retifanlimab (PD-1 inhibitor, licensed to Incyte), Flotetuzumab, Tebotelimab, Margetuximab, and IMGC936. The company operates manufacturing capabilities in Maryland and has strategic collaborations with Incyte, Gilead, and Sanofi.

Differentiator

Problem solved

Functional benefit

Brands

  • TZIELD: Disease-modifying therapy for type 1 diabetes (teplizumab-mzwv) - FDA approved for delaying decline in endogenous insulin production in children aged 8-17 with stage 3 type 1 diabetes
  • ZYNYZ

Products and services

  • Lorigerlimab (MGD019) Bispecific DART molecule simultaneously targeting PD-1 and CTLA-4 checkpoint receptors to deliver enhanced anti-tumor activity in solid tumors, with the Phase 2 LINNET study evaluating the candidate in gynecologic cancers.
  • MGC026 (B7-H3 ADC) Glycan-linked, exatecan-based antibody-drug conjugate targeting B7-H3 for the treatment of solid tumors, currently in a Phase 1 clinical study.
  • MGC028 (ADAM9 ADC) ADAM9-targeted, glycan-linked, exatecan-based antibody-drug conjugate for the treatment of solid tumors, currently in a Phase 1 clinical study.
  • MGD024 (CD123 × CD3) Bispecific DART molecule targeting CD123 and CD3 for treatment of hematological malignancies, particularly acute myeloid leukemia (AML), currently in a Phase 1 clinical trial.
  • MGC030

Quantifiable outcome

  • FDA accelerated approval of TZIELD (teplizumab) as first disease-modifying therapy for type 1 diabetes
  • +2 more outcomes

Companies that use MacroGenics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

MacroGenics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

MacroGenics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • SanoficoreStrategic or Co-development Partner · 22 June 2026MacroGenics partnered with Sanofi for TZIELD (teplizumab), a drug for delaying the decline of endogenous insulin production in children aged 8-17 with stage 3 type 1 diabetes. Sanofi holds commercialization rights while MacroGenics receives milestone payments and royalties. MacroGenics received a $24.5M regulatory milestone following FDA accelerated approval and is eligible for up to $305M in additional milestones plus single-digit royalties on global net sales.
  • Bora PharmaceuticalscoreImplementation/ SI/ Consulting Partner · 11 May 2026Bora Pharmaceuticals acquired MacroGenics' GMP drug substance manufacturing operations including the Rockville, Maryland facility and Frederick warehouse for $122.5M upfront plus up to $5M milestones. Approximately 140 employees transferred to Bora. The transaction shifts MacroGenics to a pipeline-focused model while maintaining access to manufacturing through a long-term supply arrangement. Expected to close Q3 2026.
  • Incyte CorporationcoreStrategic or Co-development PartnerGlobal collaboration for ZYNYZ (retifanlimab), a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte. Incyte markets ZYNYZ in the US for Merkel cell carcinoma and anal cancer, with European Commission approval secured for anal cancer. MacroGenics eligible for up to $540M in milestones.
  • Gilead SciencescoreStrategic or Co-development PartnerStrategic collaboration for multiple programs with MacroGenics eligible for up to $1.6 billion in potential milestones across all programs.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

MacroGenics competitors and assessment

Company assessment

Direct peers

  • Genmab: Genmab is a leading bispecific antibody platform company (Duobody® platform) and developer of approved therapeutics including epcoritamab. Highly comparable to MacroGenics given shared focus on bispecific antibody engineering and oncology/hematology indications.
  • Zymeworks: Zymeworks develops bispecific and multifunctional antibody therapeutics using its Azymetric™ and EFECT™ platforms. Directly comparable as a clinical-stage antibody engineering company pursuing similar oncology targets and partnership-driven commercialization strategies.
  • Mersana Therapeutics: Mersana develops antibody-drug conjugates using its Dolasynthen and Immunosynthen platforms, focused on oncology indications. Closely comparable to MacroGenics' ADC franchise (MGC026, MGC028) given shared modality focus and clinical-stage profile.
  • Harpoon Therapeutics: Harpoon develops T-cell engagers using its TriTAC and ProTriTAC platforms, including HP568 and other clinical-stage oncology assets. Directly comparable to MacroGenics' TRIDENT® T-cell engager platform and bispecific checkpoint approach.
  • Bolt Biotherapeutics: Bolt is a clinical-stage ADC developer using its Boltbody™ ISAC platform combining tumor-targeting antibodies with immune stimulants. Comparable to MacroGenics' ADC pipeline given shared focus on next-generation antibody-drug conjugate modalities in oncology.

Emerging players

  • CytomX Therapeutics: CytomX develops probody therapeutics — masked antibodies activated in the tumor microenvironment — with multiple partnered programs. Comparable to MacroGenics given shared focus on engineering antibody-based cancer therapeutics with proprietary platforms and major pharma collaborations.
  • Compass Therapeutics: Compass Therapeutics is a clinical-stage bispecific antibody developer (CTX-009, CTX-112) with platforms in oncology. Comparable as a smaller-scale bispecific antibody developer with similar clinical-stage profile and partnership-oriented business model.

Broad incumbents

  • Exelixis: Exelixis is a commercial-stage oncology biotech (cabozantinib/CABOMETYX) with a marketed product franchise and pipeline. Comparable to MacroGenics as an oncology-focused biotech, though Exelixis is significantly larger and operates a direct commercial model versus MacroGenics' partner-driven approach.
  • Blueprint Medicines: Blueprint Medicines is a commercial-stage precision oncology company (AYVAKIT, GAVRETO). Comparable as a similarly sized clinical/commercial biotech with partnered and proprietary oncology assets, though Blueprint has broader kinase inhibitor focus versus MacroGenics' antibody focus.
  • Iovance Biotherapeutics: Iovance is a clinical/commercial-stage cell therapy company (AMTAGVI for melanoma) at a comparable scale to MacroGenics. Comparable as a similarly-sized public biotech with FDA-approved therapy, ongoing clinical pipeline, and capital needs typical of late-stage biotech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

MacroGenics social profiles

Digital presence

MacroGenics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MacroGenics leadership team

Management profile

Number of profiles

Profiles11 records

MacroGenics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MacroGenics M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MacroGenics

What does MacroGenics do?

MacroGenics is a clinical-stage biopharmaceutical company that discovers and develops next-generation antibody-based therapeutics for cancer, hematologic malignancies, and autoimmune diseases. Its pipeline encompasses bispecific checkpoint antibodies, antibody-drug conjugates (ADCs), and T-cell engagers built on proprietary DART®, TRIDENT®, ADC, and Fc Optimization platforms, with three FDA-approved therapies (TZIELD, ZYNYZ, margetuximab) licensed to large pharma partners for global commercialization.

Is MacroGenics a public or private company?

MacroGenics is a public company. It is classified as public and is currently operating.

When was MacroGenics founded?

MacroGenics was founded in 2000. It employs 251 to 500 people.

Where is MacroGenics based?

MacroGenics is headquartered in Rockville, United States, in the North America region.

How does MacroGenics make money?

Three revenue lines are on record. Licensing and Royalty Revenue is the primary driver. The others are milestone Payments and royalty Monetization.

Who are MacroGenics's main competitors?

Direct peers on record are Genmab, Zymeworks, Mersana Therapeutics, Harpoon Therapeutics and Bolt Biotherapeutics. Emerging players are CytomX Therapeutics and Compass Therapeutics. Broad incumbents are Exelixis, Blueprint Medicines and Iovance Biotherapeutics.

Does MacroGenics have an API?

No public API is recorded for MacroGenics.

What industry is MacroGenics in?

MacroGenics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewMacroGenics Updates Clinical Pipeline, Reports $288M in Cash and Runway Through 2028MacroGenics updated its clinical pipeline, reporting $288 million in cash and investments as of September 30, 2026. MGC026 showed a 27.3% best overall response rate in SCCHN, and lorigerlimab had a 25% confirmed response in clear cell gynecologic cancer. The company cited $359 million in non-dilutive capital and plans a mid-2027 update.YahooMacroGenics (MGNX) Reports Q3 Loss, Lags Revenue EstimatesMacroGenics reported a Q3 loss of $0.34 per share, missing the consensus estimate of a $0.10 loss, and revenues of $18.67 million, down 69.89% from the prior year's $72.84 million. The company has surpassed consensus EPS estimates twice in the last four quarters.Business & FinancialMacrogenics To Participate In Upcoming Investor ConferencesMacroGenics' President and CEO Eric Risser will participate in fireside chats at the Stifel 2026 Healthcare Conference in New York on November 11 and the Evercore Healthcare Conference in Coral Gables on November 30. Management will also join one-on-one meetings at both events.TradingViewMacroGenics, Inc. (MGNX) Appoints Two Independent Board DirectorsMacroGenics appointed Emil Kuriakose and Michael Vasconcelles as independent directors, effective October 30, 2026. The appointments add oncology development experience, but the release provides no financial terms or quantified business impact.Business & FinancialMacrogenics Announces Appointments Of Emil Kuriakose, M.D., And Michael Vasconcelles, M.D., To Board Of DirectorsMacrogenics appointed Emil Kuriakose and Michael Vasconcelles to its board of directors. Both bring extensive oncology drug development experience, including leadership in clinical development, regulatory strategy, and portfolio management. The appointments aim to strengthen the board as the company advances its pipeline and strategic objectives.MarketWatchMacroGenics Stock Tumbles as Patient Death, Severe Side Effects Cloud Cancer-Drug DataMacroGenics shares fell 10% to $2.02 after Phase 2 data for lorigerlimab showed a 25% response rate but 49% of patients had Grade 3 or higher side effects, including one death. The company will test lower doses and report updated results in the first half of 2027.MarketBeatMacroGenics, Inc. (MGNX) - What Are Brokerages Thinking About This Stock?MacroGenics shares have an average analyst rating of Hold, with one sell, three holds, and two buys. The company reported Q2 EPS of $0.31, beating estimates, but revenue of $32.83 million missed the $59.14 million forecast. Insider Jeffrey Peters sold 31,105 shares at $4.15.TradingViewMacroGenics, Inc. (MGNX) Doses First Patient in Phase 1 Study of MGC030MacroGenics dosed the first patient in a Phase 1 open-label study of MGC030, a first-in-class ADC for advanced solid tumors. The study includes dose escalation to enroll up to 54 participants, with the ADC targeting an undisclosed antigen. The company's third ADC is in active clinical development.Markets DailyMadrigal Pharmaceuticals (NASDAQ:MDGL) & MacroGenics (NASDAQ:MGNX) Head-To-Head SurveyMacroGenics and Madrigal Pharmaceuticals are compared on ratings, valuation, and financials. Madrigal has a higher analyst score (2.78 vs 2.17) and lower P/E, while MacroGenics shows higher probable upside (69.34% vs 50.55%). Madrigal's lead candidate resmetirom is in Phase 3 for NASH.American Banking and Market NewsHead-To-Head Review: MacroGenics (NASDAQ:MGNX) vs. Zenas BioPharma (NASDAQ:ZBIO)MacroGenics and Zenas BioPharma are compared on financials, ownership, and analyst ratings. MacroGenics has higher revenue and earnings, but Zenas has a stronger consensus rating and higher upside. Analysts favor Zenas, citing a 71.37% upside versus 69.34% for MacroGenics.